Ovid Therapeutics (OVID) Profit After Tax (2016 - 2026)

Ovid Therapeutics (OVID) has reported Profit After Tax for 11 consecutive years, with -$15.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Profit After Tax fell 220.43% year-over-year to -$15.0 million; the trailing twelve-month figure through Jun 2026 stood at -$34.5 million (up 9.61% YoY), and the FY2025 full-year result was -$17.4 million, up 34.12% from the prior year.
• Profit After Tax grew to -$15.0 million in Q2 2026 per OVID's latest filing, from -$17.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at $9.7 million in Q4 2025 and bottomed at -$17.0 million in Q1 2026.
• Historically, Profit After Tax has averaged -$10.1 million across 5 years, with a median of -$12.1 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Profit After Tax jumped 204.68% in 2025, then plunged 220.43% in 2026.
• Over 5 years, Profit After Tax stood at -$11.5 million in 2022, then tumbled by 33.18% to -$15.3 million in 2023, then surged by 39.61% to -$9.3 million in 2024, then surged by 204.68% to $9.7 million in 2025, then plunged by 254.96% to -$15.0 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$15.0 million, -$17.0 million, and $9.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.